Related Experiment Video

Updated: May 17, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications

J J Wheler1, G S Falchook, A M Tsimberidou

  • 1Departments of Investigational Cancer Therapeutics--a Phase I, Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA. jjwheler@mdanderson.com

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|November 10, 2012
PubMed
Abstract

Insights

Epidermal growth factor receptor (EGFR) aberrations were found in 1.6% of diverse advanced cancers beyond non-small-cell lung cancer. EGFR inhibitors showed potential for prolonged stable disease in these patients.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) mutations are key biomarkers for EGFR inhibitor efficacy in non-small-cell lung cancer (NSCLC).
  • The presence and impact of EGFR aberrations in other advanced solid tumors remain less understood.

Purpose of the Study:

  • To investigate the frequency and spectrum of EGFR aberrations in a diverse patient cohort with advanced cancers.
  • To explore the potential clinical benefit of EGFR inhibitors in non-NSCLC patients with EGFR aberrations.

Main Methods:

  • Patients referred to a phase I clinic were screened for EGFR mutations.
  • Tumor samples were analyzed for EGFR aberrations.
  • Response to EGFR inhibitor therapy was assessed in relevant cases.

Main Results:

  • EGFR aberrations were detected in 3.5% of 958 patients, most commonly in NSCLC (16%).
  • In non-NSCLC patients (1.6%), EGFR aberrations were identified in various solid tumors, including adrenocortical, skin, breast, and sarcoma.
  • Two non-NSCLC patients with EGFR aberrations achieved stable disease for 6 and 7 months when treated with an EGFR inhibitor.

Conclusions:

  • EGFR aberrations occur in a small but significant percentage of diverse advanced solid tumors.
  • EGFR inhibitors may offer clinical benefit, including prolonged stable disease, in select non-NSCLC patients with EGFR aberrations.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...